Sabrina Spinosa‐Guzman

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Bonaventura Clotet, Nicholas Bellos, Jean‐Michel Molina et al. · The Lancet · 2007 · 480 citations

Treatment And Prevention, Week 48, Antiviral Drug Development +9

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

Roberto Ortiz, Edwin DeJesus, Homayoon Khanlou et al. · AIDS · 2008 · 382 citations

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

José Valdez Madruga, Daniel Berger, Marilyn McMurchie et al. · The Lancet · 2007 · 330 citations

Treatment And Prevention, Antiviral Drug Development, Antiviral Therapy +5

The Effect of Different Meal Types on the Pharmacokinetics of Darunavir (TMC114)/Ritonavir in HIV‐Negative Healthy Volunteers

Vanitha Sekar, Dries Kestens, Sabrina Spinosa‐Guzman et al. · The Journal of Clinical Pharmacology · 2007 · 94 citations

Nutrition, Darunavir C, Medicine +13

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients

Sandra De Meyer, Erkki Lathouwers, Inge Dierynck et al. · AIDS · 2009 · 58 citations